PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.
PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.
PharmGKB contains no Clinical Variants that meet the highest level of criteria.
Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.
The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.
|Alternate Names:||BMK1 kinase; PRKM7; extracellular-signal-regulated kinase 5|
|Alternate Symbols: ||BMK1; ERK5|
|PharmGKB Accession Id:||PA30625|
|Cytogenetic Location:||chr17 : p11.2 - p11.2|
|GP mRNA Boundary†:||chr17 : 19281034 - 19286857|
|GP Gene Boundary†:||chr17 : 19271034 - 19289857|
PharmGKB Curated Pathways
Pathways created internally by PharmGKB based primarily on literature evidence.
VEGF Signaling Pathway
Model endothelial cell displaying genes of the VEGF signalling pathway and the sites at which bevacizumab, sorafenib, sunitinib, brivanib and cilengitide are known to act.
Links to non-PharmGKB pathways.
- control of skeletal myogenesis by hdac and calcium/calmodulin-dependent kinase (camk) - (BioCarta via Pathway Interaction Database)
- ERK/MAPK targets - (Reactome via Pathway Interaction Database)
- mapkinase signaling pathway - (BioCarta via Pathway Interaction Database)
- role of erk5 in neuronal survival pathway - (BioCarta via Pathway Interaction Database)
- Signalling to ERK5 - (Reactome via Pathway Interaction Database)
- Trk receptor signaling mediated by the MAPK pathway - (Pathway Interaction Database NCI-Nature Curated)
Publications related to MAPK7: 4
The following icons indicate that data of a certain type is available:
- DG Dosing Guideline information is available
- DL Drug Label information is available
- CA High-level Clinical Annotation is available
- VA Variant Annotation is available
- VIP VIP information is available
- PW Pathway is available
[ close ]
||SNPs in genes coding for ROS metabolism and signalling in association with docetaxel clearance. The pharmacogenomics journal. 2010. Edvardsen H, et al.|
||Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions. Nature genetics. 2007. Winkelmann Juliane, et al.|
||BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer research. 2004. Wilhelm Scott M, et al.|
||The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells. The Journal of biological chemistry. 1997. Kroll J, et al.|